Swiss biotech Nouscom raises €120 million for cancer-interception vaccine trial
Representative image: Vector8DIY / Pixabay
Basel biotech Nouscom raised €120 million ($135 million) in a Series D on October 19, 2026 to take its NOUS-209 vaccine for Lynch syndrome carriers into a larger trial.
What Happened
Nouscom, a clinical-stage biotechnology company based in Basel, Switzerland, announced on Monday, October 19, 2026 that it had raised €120 million (about $135 million) in an oversubscribed Series D funding round. The round was co-led by M Ventures and Revelation Partners, with new investors including Angelini Industries and the European Investment Bank. The company said the money will fund a global trial of its lead candidate, NOUS-209, an experimental vaccine designed to intercept, or stop early, cancers in people with Lynch syndrome, an inherited condition that raises cancer risk.
Key Facts
- Amount: €120 million (about $135 million), Series D, announced October 19, 2026.
- Co-lead investors: M Ventures and Revelation Partners; new investors include Angelini Industries and the European Investment Bank.
- Use of funds, according to the company: a global trial of NOUS-209 in Lynch syndrome carriers.
- Earlier Phase 1b/2 results supported moving NOUS-209 into a registration-enabling Phase 2/3 trial, the company has said.
- The US Food and Drug Administration has given NOUS-209 Fast Track designation, which allows more frequent contact with the regulator during development.
- Nouscom will present longer-term follow-up and re-treatment data at the ESMO Congress in Madrid, held October 23 to 27, 2026.
- One report noted that the earlier trial had no control group, so a preventive effect has not been proven.
Why It Matters
Most cancer medicines are used after a tumour has been found. Nouscom is working on the opposite end: "cancer interception" means trying to stop cancer from developing in people known to be at high risk, before a tumour appears. People with Lynch syndrome carry inherited changes in genes that normally repair errors in DNA. As a result, they face a higher lifetime risk of several cancers, especially of the bowel and womb, and they usually rely on frequent screening such as colonoscopies.
NOUS-209 is a type of immunotherapy, a treatment that trains the body's immune system to recognise threats. According to the company, NOUS-209 is designed to train the immune system to recognise and clear abnormal cells in Lynch syndrome carriers before they become cancer. That is the company's description of how the vaccine is meant to work. The key limit is evidence: early trials have mainly measured safety and immune responses, and without a comparison group they cannot show that the vaccine prevents cancer. That question is what the larger trial is meant to answer.
The funding is also a signal for the start-up and investment world. A large, oversubscribed late-stage round for a European biotech, with a public lender such as the European Investment Bank on board, shows that investors are willing to back long, expensive prevention trials when early data and regulatory support line up. For Indian biotech founders and researchers, the deal is a reminder that cancer prevention for high-risk genetic groups is becoming a funded field in its own right, with room for work on genetic testing, screening and trial services.
| Item | Detail |
|---|---|
| Company | Nouscom, Basel, Switzerland |
| Round | Series D, €120 million (about $135 million), October 19, 2026 |
| Co-leads | M Ventures, Revelation Partners |
| New investors | Angelini Industries, European Investment Bank |
| Lead product | NOUS-209, for Lynch syndrome carriers |
Impact
Short-term: Nouscom will present new follow-up data at ESMO in Madrid between October 23 and 27, and start preparing the larger global trial. Doctors and patient groups will look closely at the data on re-treatment and the durability of immune responses.
Long-term: If a controlled trial shows that NOUS-209 lowers cancer rates, it could change care for Lynch syndrome carriers and open the way for similar vaccines for other inherited cancer risks. If it does not, the funding round will be remembered as a costly test of an unproven idea. Either way, the result will take years.
Who is affected: People with Lynch syndrome and their families, cancer genetics clinics and screening programmes, biotech investors, and researchers working on cancer prevention and immunotherapy worldwide.
Key Takeaway
Nouscom's €120 million Series D, announced on October 19, 2026, funds a larger trial of NOUS-209, a vaccine meant to stop cancers in Lynch syndrome carriers, whose preventive effect is still to be proven.
Questions and Answers
How much did Nouscom raise and who invested?
Nouscom raised €120 million, about $135 million, in a Series D round announced on October 19, 2026. M Ventures and Revelation Partners co-led it, and new investors included Angelini Industries and the European Investment Bank.
What is NOUS-209?
NOUS-209 is Nouscom's experimental immunotherapy vaccine, designed to train the immune system to target abnormal cells in people with Lynch syndrome so that cancers can be stopped early. It has FDA Fast Track designation but is not approved.
What is Lynch syndrome?
Lynch syndrome is an inherited condition caused by changes in genes that repair DNA errors. People who carry it have a higher lifetime risk of several cancers, especially bowel and womb cancer, and are usually advised to have regular screening.
Has NOUS-209 been shown to prevent cancer?
No. Earlier trials mainly measured safety and immune responses and had no control group. The larger trial funded by this round is meant to test whether the vaccine actually reduces cancer.
Disclaimer: Prepared by the Peepals newsroom from publicly available sources with AI assistance. Information is accurate to the best of our knowledge at the time of publication and may change. Images may be representative. Not professional advice. Report an error via our contact page.
Sourced and fact-checked by the Peepals Global Editorial Team
Reported, fact-checked and published by the Peepals Global Editorial Team.
